We're sunsetting PodQuest on 2025-07-28. Thank you for your support!

cover of episode #62 - Keith Flaherty, M.D.: Deep dive into cancer—History of oncology, novel approaches to treatment, and the exciting and hopeful future

#62 - Keith Flaherty, M.D.: Deep dive into cancer—History of oncology, novel approaches to treatment, and the exciting and hopeful future

2019/7/15

The Peter Attia Drive

AI Chapters

Chapters

Shownotes Transcript

No transcript made for this episode yet, you may request it for free.

#62 - Keith Flaherty, M.D.: Deep dive into cancer—History of oncology, novel approaches to treatment, and the exciting and hopeful future

The Peter Attia Drive

Growing up around medicine, and finding a career that you love?

Medicine as a career, limitations of the med school teaching approach, and the dynamic and accelerating field of medicine and technology

Explaining chemotherapy, radiation, and how a cancer develops

Surgical oncology, cure rate of solid tumors, and survival rate after tumor removal

25 years after the War on Cancer is declared, gene sequencing, and why Keith’s was fascinated by the HIV case study

Cancer immunotherapy: History, how it works, and why some cancers respond and others don’t?

MHC complexes, and cancer cloaking mechanisms

Comparative biology of cancer: Why some cancer can evade immune detection better than others?

What we learned from the Cancer Genome Atlas Project

Defining targeted therapy, HER2 breast cancer, chronic leukemia, and the translocation of chromosomes

Tumor protein P53, the most famous tumor suppressor gene and its ubiquity in cancer

Activated oncogenes, the RAS pathway, PI3 kinase, RAF gene, and Keith’s “aha moment”

Advice for starting your career as a scientist/clinician

Fusion-driven cancers, targeted therapy, and the Bcr-Abl/chronic myelogenous leukemia case study

Targeted therapy for fusion-driven solid tumors, adjuvant systemic therapy, and the HER2 breast cancer example

Advancing melanoma treatment, survival, and cure rates with BRAF-MEK combo therapy

The fundamental pillars of cancer growth and survival, and the toolkit we need to attack cancer from all angles

Peter’s clinical framework for thinking about cancer and how Keith might improve it, and how the biotech environment is hampering our ability to put together novel cancer treatments

How useful is CRISPR in terms of tumor suppressing?

Liquid biopsies as a therapeutic monitoring tool

Stem cell therapy: The efficacy and potential risks

Aging and cancer: Is cancer inevitable?

Vitamin D supplements, sun exposure, melanoma, and exercise

How and why Keith has straddled the line between science/research and industry/drug companies, and the importance of getting more voices of practitioners at the table

Shownotes Transcript

#62 - Keith Flaherty, M.D.: Deep dive into cancer—History of oncology, novel approaches to treatment, and the exciting and hopeful future 02:57:28 Share

The Peter Attia Drive

Growing up around medicine, and finding a career that you love?

Medicine as a career, limitations of the med school teaching approach, and the dynamic and accelerating field of medicine and technology

Explaining chemotherapy, radiation, and how a cancer develops

Surgical oncology, cure rate of solid tumors, and survival rate after tumor removal

25 years after the War on Cancer is declared, gene sequencing, and why Keith’s was fascinated by the HIV case study

Cancer immunotherapy: History, how it works, and why some cancers respond and others don’t?

MHC complexes, and cancer cloaking mechanisms

Comparative biology of cancer: Why some cancer can evade immune detection better than others?

What we learned from the Cancer Genome Atlas Project

Defining targeted therapy, HER2 breast cancer, chronic leukemia, and the translocation of chromosomes

Tumor protein P53, the most famous tumor suppressor gene and its ubiquity in cancer

Activated oncogenes, the RAS pathway, PI3 kinase, RAF gene, and Keith’s “aha moment”

Advice for starting your career as a scientist/clinician

Fusion-driven cancers, targeted therapy, and the Bcr-Abl/chronic myelogenous leukemia case study

Targeted therapy for fusion-driven solid tumors, adjuvant systemic therapy, and the HER2 breast cancer example

Advancing melanoma treatment, survival, and cure rates with BRAF-MEK combo therapy

The fundamental pillars of cancer growth and survival, and the toolkit we need to attack cancer from all angles

Peter’s clinical framework for thinking about cancer and how Keith might improve it, and how the biotech environment is hampering our ability to put together novel cancer treatments

How useful is CRISPR in terms of tumor suppressing?

Liquid biopsies as a therapeutic monitoring tool

Stem cell therapy: The efficacy and potential risks

Aging and cancer: Is cancer inevitable?

Vitamin D supplements, sun exposure, melanoma, and exercise

How and why Keith has straddled the line between science/research and industry/drug companies, and the importance of getting more voices of practitioners at the table

Shownotes Transcript

#62 - Keith Flaherty, M.D.: Deep dive into cancer—History of oncology, novel approaches to treatment, and the exciting and hopeful future